Tetraphase Pharmaceu (TTPH) 4.49 $TTPH Tetraphase

New Post Public Reply Private Reply Replies (0) Message Board

Jul 11, 2016 at 5:13 AM

Tetraphase Pharmaceu (TTPH) 4.49 $TTPH

Tetraphase Pharmaceuticals to Present at 2016 JMP Securities Life Sciences Conference
GlobeNewswire - Wed Jun 15, 7:00AM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the JMP Securities Life Sciences Conference on Wednesday, June 22, 2016 at 1:30 p.m. Eastern Time at The St. Regis New York Hotel in New York City.
TTPH: 4.49 (+0.11)

Tetraphase Pharmaceuticals Announces Presentation of Data at ASM Microbe 2016
GlobeNewswire - Mon May 23, 7:30AM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced seventeen data presentations at the American Society of Microbiology (ASM) Microbe 2016 Conference, taking place June 16-20 in Boston, MA. Presentations will include information about the company's lead drug candidate, eravacycline, as well as data from its TP-271 program.
TTPH: 4.49 (+0.11)

The Zacks Analyst Blog Highlights: Medivation, Anacor, Aduro, Trevena and Tetraphase
Zacks Equity Research - Zacks Investment Research - Fri May 20, 8:30AM CDT
The Zacks Analyst Blog Highlights: Medivation, Anacor, Aduro, Trevena and Tetraphase
MDVN: 62.10 (-0.64), TTPH: 4.49 (+0.11), TRVN: 7.13 (+0.19), ADRO: 12.66 (+0.22), ANAC: 99.06 (-0.14)

Biotech Stock Roundup: Pfizer to Buy Anacor for $5.2B, Pipeline Setbacks for Aduro, Trevena
Arpita Dutt - Zacks Investment Research - Thu May 19, 2:36PM CDT
Key highlights in the biotech sector include the acquisition agreement between Anacor (ANAC) and Pfizer as well as data presentations.
MDVN: 62.10 (-0.64), TRVN: 7.13 (+0.19), TTPH: 4.49 (+0.11), VRTX: 88.96 (-1.09), ADRO: 12.66 (+0.22), AMGN: 161.10 (+4.51), ANAC: 99.06 (-0.14)

Nordstrom and Wal-Mart fall, Shake Shack and Nvidia jump
AP - Fri May 13, 3:36PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday:
TTPH: 4.49 (+0.11), SHAK: 36.79 (+0.77), WMT: 73.84 (+0.31), JWN: 40.32 (+1.17), CXR.TO: 27.25 (-0.11), NTK: 87.25 (+0.50), CXRX: 20.90 (-0.13), NVDA: 50.85 (+1.96)

Tetraphase Pharmaceuticals Provides Update on Eravacycline Regulatory and Development Status
GlobeNewswire - Thu May 12, 3:05PM CDT
- Additional phase 3 clinical trial in cIAI planned to support NDA filing -
TTPH: 4.49 (+0.11)

Tetraphase Pharmaceuticals Reports First Quarter 2016 Financial Results
GlobeNewswire - Wed May 04, 3:30PM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today reported financial results for the first quarter ended March 31, 2016.
TTPH: 4.49 (+0.11)

Buying Stocks: Investors Are Considering These on Thursday April 7
ACCESSWIRE - Thu Apr 07, 12:34PM CDT
MIAMI, FL / ACCESSWIRE / April 7, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. CANN, COOL, TTPH, and EKSO have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
TTPH: 4.49 (+0.11), COOL: 0.72 (unch)

Tetraphase Pharmaceuticals to Present Data at 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
GlobeNewswire - Thu Apr 07, 7:00AM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced five data presentations at the 26 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), taking place April 9-12 in Amsterdam, Netherlands. Presentations will include information about the company's lead drug candidate, eravacycline, as well as data from its preclinical TP-6076 program.
TTPH: 4.49 (+0.11)

Tetraphase Pharmaceuticals to Present at Needham Conference 2016
GlobeNewswire - Wed Apr 06, 7:00AM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the 15 Annual Needham & Co. Healthcare Conference on Wednesday, April 13, 2016 at 11:20 a.m. Eastern Time at The Westin Grand Central Hotel in New York City.
TTPH: 4.49 (+0.11)

EQUITY UPDATE: Goldberg Law PC Files Securities Class Action Lawsuit against Tetraphase Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
BusinessWire - Fri Mar 25, 2:14PM CDT
Goldberg Law PC (www.Goldberglawpc.com) announces that it has filed a class action lawsuit against Tetraphase Pharmaceuticals, Inc. ("Tetraphase" or the "Company"

(Nasdaq: TTPH). Investors who purchased or otherwise acquired shares between March 5, 2015 and September 8, 2015, (the "Class Period"

, are encouraged to contact the firm in advance of the March 28, 2016, lead plaintiff motion deadline. The new lawsuit has been filed on behalf of options purchasers and sellers.
TTPH: 4.49 (+0.11)

IMPORTANT DEADLINE REMINDER: Khang & Khang LLP Announces The Filing Of A Securities Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm
BusinessWire - Fri Mar 25, 9:50AM CDT
Khang & Khang LLP (the "Firm"

announces that a class action lawsuit has been filed against Tetraphase Pharmaceuticals, Inc. ("Tetraphase" or the "Company"

(Nasdaq: TTPH). Investors who purchased or otherwise acquired shares between March 5, 2015 and September 8, 2015, inclusive (the "Class Period"

, are encouraged to contact the Firm prior to the March 28, 2016, lead plaintiff motion deadline.
TTPH: 4.49 (+0.11)

DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Tetraphase Pharmaceuticals, Inc. and Lead Plaintiff Deadline: March 28, 2016
ACCESSWIRE - Fri Mar 25, 9:01AM CDT
NEW YORK, NY / ACCESSWIRE / March 25, 2016 / Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a securities class action has been filed in the United States District Court for the District of Massachusetts on behalf of those who purchased shares of Tetraphase Pharmaceuticals, Inc. ("Tetraphase" or the "Company"

(NASDAQ: TTPH), during the period between March 5, 2015 and September 9, 2015 inclusive (the "Class Period"

.
TTPH: 4.49 (+0.11)

UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Shareholders of Tetraphase Pharmaceuticals Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of March 28, 2016 - TTPH
PR Newswire - Thu Mar 24, 1:47PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
TTPH: 4.49 (+0.11)

EQUITY ALERT UPDATE: Rosen Law Firm Expands Securities Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc. on Behalf of Options Purchasers and Sellers
BusinessWire - Wed Mar 23, 6:07PM CDT
Rosen Law Firm, a global investor rights law firm, has filed a class action lawsuit on behalf of all purchasers of the common stock and call options and sellers of put options of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) from March 5, 2015 through September 8, 2015, all dates inclusive (the "Class Period"

. The lawsuit seeks to recover damages for Tetraphase Pharmaceuticals investors under the federal securities laws.
TTPH: 4.49 (+0.11)

Lifshitz & Miller Law Firm Announces Investigation of comScore, Inc., LendingClub Corporation, Rockwell Medical, Inc., ROFIN-SINAR Technologies, Inc., Tailored Brands, Inc., Tangoe, Inc., and Tetraphase Pharmaceuticals, Inc.
PR Newswire - Tue Mar 22, 8:01PM CDT
comScore, Inc. (SCOR)
TTPH: 4.49 (+0.11), TNGO: 7.76 (+0.21), LC: 4.32 (+0.07), TLRD: 13.24 (+0.47), RSTI: 31.99 (+0.15), RMTI: 8.06 (+0.26), SCOR: 26.60 (+0.75)

INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc. and Reminds Investors with Losses to Contact the Firm
BusinessWire - Tue Mar 22, 12:13PM CDT
Lundin Law PC announces a class action lawsuit has been filed against Tetraphase Pharmaceuticals, Inc. ("Tetraphase" or the "Company"

(NASDAQ: TTPH) concerning possible violations of federal securities laws between March 5, 2015 and September 8, 2015. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the March 28, 2016, lead plaintiff motion deadline.
TTPH: 4.49 (+0.11)

INVESTOR ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Lawsuit Involving Tetraphase Pharmaceuticals Inc. and a Lead Plaintiff Deadline of March 28, 2016 - TTPH
GlobeNewswire - Tue Mar 22, 10:09AM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) securities between March 5, 2015 and September 8, 2015.
TTPH: 4.49 (+0.11)

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc. And Reminds Investors With Losses To Contact The Firm
BusinessWire - Fri Mar 18, 9:38PM CDT
Lundin Law PC announces a class action lawsuit has been filed against Tetraphase Pharmaceuticals, Inc. ("Tetraphase" or the "Company"

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Revolutionizing Talent Matching with Match2's Latest Upgrades In the churn of today's recruiting jungle, candidates and employers have been grappling with disjointed systems and outdated approaches. Well, Match2 is cutting through that noise with some hefty upgrades. It's got some new toys in the shed—specifically, a beefed-up Universal Candidate Profile™ and an...

Lundbeck's Board Leadership Transitions into New Era

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Dickinson Brands Celebrates Witch Hazel Legacy with Event

Witch Hazel's Timeless Appeal You don’t get to celebrate over one and a half centuries of a product without doing something right. Dickinson Brands Inc. is throwing a bash worth noticing as they mark the sixth annual National Witch Hazel Day on October 21st. It’s a head-nod to the versatile witch hazel, a product that’s been part of New England's heritage since the...

Faith and Resilience in China: The Legacy of the Long March

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Kansai Medical Ushers in New Era of Cancer Research

Breaking Ground in Cancer Treatment Trials I've seen some thrilling breakthroughs in my time following the pharmaceutical industry, but what Kansai Medical University and Daiichi Sankyo are doing elevates the game. They're rolling out the first patient dose of DS1025 in Osaka, Japan—a move that marks the onset of a global Phase 1 clinical trial. This is no ordinary...

Angels on Call Sets Benchmark for Specialized Homecare

Pioneering a New Standard in Homecare Take a gander at Angels on Call Homecare. They're not just another name in a crowded field; they've carved out a niche—specializing in elite care for Dementia and Parkinson's patients. You don't usually hear homecare and innovation in the same breath, do you? But these folks are setting a fresh benchmark. Independent feedback has...

Antheia Secures $80M for Critical Medicine Onshoring

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Alpha Rising Joins RFP: A Strong AI-Fueled Expansion

The Shift: From LPL to AI-Driven Innovation Hold onto your hats, because Alpha Rising Wealth Management has taken a significant leap from the traditional ship of LPL Financial to the cutting-edge shores of Rothschild Financial Partners (RFP). It's a move that's painting the walls in Scottsdale, Arizona with $250 million in client assets, all set to benefit from a modern,...

New Chapter Recovery Garners Key Accreditations

Accreditations That Matter It's not every day a treatment facility pops its head up with credentials that weigh like a ton of bricks. New Chapter Recovery in New Jersey just snagged two heavy hitters: Joint Commission accreditation and LegitScript certification. These badges don’t just glimmer for show; they’re the market's assurance against empty promises—an...

AI-Designed Antivirals: A Brave New World

Pushing the Boundaries with AI in Drug Discovery It seems some smart folks over in South Korea are giving the pharma game a fresh twist, pitting artificial intelligence against viral invaders in a newfangled brawl. Professors from Korea University have managed to blend AI's computing prowess with good ol' lab doggedness to sniff out potential antiviral compounds. The...